News
CLDX
34.22
-3.28%
-1.16
Benjamin Graham Detailed Fundamental Analysis - CLDX
NASDAQ · 2d ago
Weekly Report: what happened at CLDX last week (0520-0524)?
Weekly Report · 3d ago
Weekly Report: what happened at CLDX last week (0513-0517)?
Weekly Report · 05/20 11:08
Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Dow Jones · 05/15 14:51
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Benzinga · 05/15 14:40
Buy Rating Affirmed for Celldex on Promising Barzolvolimab Trials in Inflammatory Diseases
TipRanks · 05/15 13:25
CELLDEX ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF BARZOLVOLIMAB IN PRURIGO NODULARIS
Reuters · 05/15 12:01
Weekly Report: what happened at CLDX last week (0506-0510)?
Weekly Report · 05/13 11:17
Celldex Therapeutics: Rising High, With Room For Further Growth
Celldex Therapeutics is a biopharmaceutical company with a strong pipeline of potential treatments. The company has a solid financial outlook and is valued at almost $3 billion as a phase 2 company. The main pipeline candidate is an autoimmune disease-targeting antibody targeting KIT.
Seeking Alpha · 05/10 14:44
Analysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX), Siemens Healthineers AG (OtherSEMHF) and uniQure (QURE)
TipRanks · 05/08 14:51
Celldex Therapeutics: A Strong Buy on Impressive Barzolvolimab Results and Promising Pipeline
TipRanks · 05/08 03:56
Unveiling 4 Analyst Insights On Celldex Therapeutics
Celldex Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of cancer-targeting biologics. 4 analysts provided ratings for CelldexTherapeutics in the latest quarter. The 12-month price targets for the company have increased by 10.07% to $79.25 and $90.00.
Benzinga · 05/07 20:00
Buy Rating Affirmed for Celldex on Strong Barzolvolimab Trial Results and Positive Outlook
TipRanks · 05/07 13:46
Celldex Buy Rating Affirmed by Analyst Joseph Pantginis on Strong Q1 Performance and Promising Drug Pipeline
TipRanks · 05/07 11:47
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024
Celldex Therapeutics reported results for the first quarter of 2024. The company reported earnings per share of -56 cents and revenue of $156,000. This was 83.04% worse than the analyst estimate for the same period. Celldex is a biopharmaceutical company.
Investorplace · 05/07 01:55
Celldex GAAP EPS of -$0.56, revenue of $0.16M
Seeking Alpha · 05/06 20:41
CellDex Therapeutics, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/06 20:29
*Celldex Therapeutics: Cash, Cash Equivalents and Marketable Securities at March 31 Sufficient to Meet Estimated Working Cap Requirements and Fund Current Planned Ops Through 2027 >CLDX
Dow Jones · 05/06 20:02
CELLDEX REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 05/06 20:01
CELLDEX THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2024 WERE $823.8 MLN
Reuters · 05/06 20:01
More
Webull provides a variety of real-time CLDX stock news. You can receive the latest news about Celldex Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.